Strategic partnerships Strong interest from venture philanthropy and strategic investors (United Mitochondrial Disease Foundation, Angelini Ventures, Mubadala) indicates potential for co-development, funding-enabled collaborations, and access to rare disease networks that can accelerate clinical programs and lead to co-marketing or milestone-based deals.

Clinical progress Recent preclinical data presentations at MDA and ObesityWeek, along with a lead candidate PX578, signal near-term milestones that can be paired with strategic diligence workstreams and informed contact plans to engage large biopharma with mitochondrial and neuromuscular portfolios.

Targeted markets Focus on POLG and mtDNA depletion related diseases positions Pretzel to pursue patients with high unmet need and connect with specialty centers and payer networks focused on mitochondrial disorders, rare diseases, neurology, and metabolic conditions for potential collaborations or out-licensing discussions.

Technical stack leverage Utilize existing capabilities in RT-qPCR, Cryo-EM collaboration via SciLifeLab, and project management tools to propose joint research services, tool development partnerships, or sponsored research agreements that can create recurring revenue streams and de-risk external collaborations.

Funding readiness A combined funding profile of significant Series A backing plus ongoing investor interest suggests a favorable window for milestone-driven partnerships, co-development deals, and early access programs with pharma companies seeking mitochondria-focused innovation.